www.brainwork.md – Accredited eLearning for neurologists.

An online neurology network at your fingertips!

Join and become a member of our community for access to:

Up-to-the-minute reporting from international conferences, Accredited CME courses by world-renowned experts, Coverage of the latest scientific and clinical information,
… and much more!

JOIN

Latest news

3rd December 2021

Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis

https://www.brainwork.md/content/uploads/2021/12/Brainwork-Long-term-survival-participants-CENTAUR-trial-sodium-phenylbutyrate-taurursodiol-amyotrophic-lateral-sclerosis.jpg 960 640 Brainwork Brainwork https://secure.gravatar.com/avatar/c65b553db7114a8936dd574a5706aa6f?s=96&d=mm&r=g 3rd December 2021 3rd December 2021

The CENTAUR phase 2, randomised, placebo-controlled trial included patients with amyotrophic lateral sclerosis (ALS) who received a fixed dose formulation of sodium phenylbutyrate-taurursodiol (PB-TURSO). The trial showed results of a slowed functional decline. Background…

Getting the complete clinical picture: A closer look at smouldering MS

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-02_inflammation-.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 1st November 2021

Multiple sclerosis (MS) is an inflammatory disease that is often dominated by relapsing-remitting symptoms.1 However, inflammation is not only present in acute and relapsing MS,…

Howard Donohue, PhD
0

29th October 2021

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-04_antibody.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 1st November 2021

Natalizumab 300 mg every 4 weeks (Q4W) is approved for the treatment of relapsing-remitting multiple sclerosis (MS). In patients previously exposed to the JC virus,…

Howard Donohue, PhD
0

29th October 2021

Aquaporin-4-positive neuromyelitis optica spectrum disorder: A favourable long-term benefit-risk profile of eculizumab treatment

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-06-20211013_illustration-05_nerve.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 1st November 2021

Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory disease that typically affects the optic nerves and spinal cord.1,2 At least two-thirds of cases are…

Howard Donohue, PhD
0

22nd October 2021

Integrative medicine for multiple sclerosis: Outcomes from the Inspire MS program

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-06-20211019_illustration-01_Wellness.png 5692 3201 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 22nd October 2021 29th October 2021

A growing body of evidence suggests that integrative medicine (IM) modalities can enhance the comprehensive care of patients with multiple sclerosis (MS). Thirty to eighty…

Howard Donohue, PhD
0

BrainworkFollow

Brainwork @brainwork_md·

3 Dec

New PB-TURSO shows benefit in overall survival for patients with #ALS. Read the full article: https://www.brainwork.md/long-term-survival-of-participants-in-the-centaur-trial-of-sodium-phenylbutyrate-taurursodiol-in-amyotrophic-lateral-sclerosis/

Brainwork @brainwork_md·

1 Nov

Inflammation is not only present in acute and relapsing #multiplesclerosis (MS), but also in the secondary and progressive disease. At #ECTRIMS 2021, Dr Fox, (Cleveland Clinic) discussed the impact of smouldering inflammation in #MS: https://bit.ly/3w4Q7Wp

Brainwork @brainwork_md·

1 Nov

At least 2/3 of cases of #neuromyelitis optica spectrum disorder (#NMOSD) are associated with AQP4-IgG and complement-mediated CNS damage. At ECTRIMS 2021, Prof. Wingerchuk (Mayo Clinic) presented long-term data on #eculizumab for AQP4-positive NMOSD. https://bit.ly/3BEESp2

Brainwork @brainwork_md·

1 Nov

PML is a risk with #natalizumab treatment in patients previously exposed to the JC virus. At ECTRIMS 2021, Dr. John Foley presented data from #NOVA – the first randomized controlled trial on expanded interval dosing with natalizumab.https://bit.ly/2Y6EkKM

Brainwork @brainwork_md·

29 Oct

To optimize control of disease activity in people with #multiplesclerosis, it is important to study long-term efficacy of treatments. At #ECTRIMS 2021, Professor Mathias Mäurer discussed recent long-term data in patients treated with cladribine tablets. https://bit.ly/3bo08Ex

Courses

Myotonic Disorders

In this course, accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and the Swiss Medical Association (FMH), a healthcare professional will provide the participant with an overview of myotonic disorders.

select course

Management of Epilepsy during Pregnancy

In this course, accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and the Swiss Medical Association (FMH), healthcare professionals will provide the participant with a clear understanding of the important considerations for women with epilepsy when planning a pregnancy.

select course

Prognosis and Treatment Strategy in RRMS

In this course, accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and the Swiss Medical Association (FMH), healthcare professionals will provide the participant with an overview of the applications of machine learning approaches to stroke diagnosis and monitoring.

select course

view more courses

Events

27th October 2017

Welcome to Brainwork

https://www.brainwork.md/content/uploads/2017/10/MPR426-Brainwork-illustrations-articles-V00-02-20171027_neurons.png 899 506 Prof. Dr. Krassen Nedeltchev Prof. Dr. Krassen Nedeltchev https://secure.gravatar.com/avatar/aaadc696c1b66fe476051e7e4012d01a?s=96&d=mm&r=g 27th October 2017 27th October 2017

Prof. Dr. Krassen Nedeltchev
3
7

25th April 2018

A conversation with Dr Jens Kuhle

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 25th April 2018 13th July 2018

Lutz Achtnichts, MD
0
2

6th March 2018

ZINBRYTA^® (daclizumab) voluntarily withdrawn from markets worldwide

https://www.brainwork.md/content/uploads/2018/03/Brainwork-MS.jpg 1600 1067 Julien Ferrari, PharmD, PhD Julien Ferrari, PharmD, PhD https://secure.gravatar.com/avatar/3b67ea7b895dced9b9ed9795a9851ab4?s=96&d=mm&r=g 6th March 2018 13th July 2018

Julien Ferrari, PharmD, PhD
0
2

30th April 2018

Huntington’s disease: Antisense drug showing promising results

https://www.brainwork.md/content/uploads/2018/04/Brainwork-HuntingtonsDisease.jpg 4288 3216 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 30th April 2018 13th July 2018

Lutz Achtnichts, MD
0
1

View more events

An online neurology network at your fingertips!

Latest news

Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis

Getting the complete clinical picture: A closer look at smouldering MS

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

Aquaporin-4-positive neuromyelitis optica spectrum disorder: A favourable long-term benefit-risk profile of eculizumab treatment

Integrative medicine for multiple sclerosis: Outcomes from the Inspire MS program

Courses

Myotonic Disorders

Management of Epilepsy during Pregnancy

Prognosis and Treatment Strategy in RRMS

Events

Welcome to Brainwork

A conversation with Dr Jens Kuhle

ZINBRYTA® (daclizumab) voluntarily withdrawn from markets worldwide

​Huntington’s disease: Antisense drug showing promising results

ZINBRYTA^® (daclizumab) voluntarily withdrawn from markets worldwide

Huntington’s disease: Antisense drug showing promising results